Novavax said partnerships with Sanofi and Pfizer could extend its cash runway into the 2030s, marking a significant strategic pivot for the company as it moves beyond its dependence on COVID-19 vaccines.
Speaking at Citi's Biopharma Back to School Summit on September 10, CEO John Jacobs said the company has transformed over the past three-and-a-half years "from a company that was solely focused on producing and commercializing a vaccine for COVID to one that's now out-licensing our technology, partnering our tech, expanding the utility of our technology" beyond infectious disease and into oncology.
Under the Sanofi arrangement, Novavax stands to receive up to $200 million in near-term milestone payments, excluding royalties. That includes $125 million tied to the initiation of a pivotal COVID-flu combination vaccine trial and $75 million linked to technology transfer, which would allow Sanofi to take over full manufacturing of NUVAXOVID. Jacobs noted an anticipated $75 million tech-transfer milestone payment is expected in 2027.
A separate agreement with Pfizer includes a $30 million upfront payment already received, with up to $500 million in total milestone potential across two selected therapeutic fields. Each field carries up to $70 million in clinical development milestones and up to $180 million in sales-related milestones, plus royalties payable for two decades after approval.
The financial context underscores the shift. Novavax reported revenue of $413.8 million over the trailing twelve months as of Q2 2026, down 61.6% year over year. The company has cut operating expenses by 80% to 90% while maintaining core R&D capabilities, according to management.
CFO Jim Kelly pointed to industry validation for Novavax's Matrix-M adjuvant platform. "Two of the four major vaccine players have identified Matrix-M as an important contributor to their vaccine innovation," he said, referencing the Sanofi and Pfizer deals.
Novavax is exploring Matrix-M's adjuvant properties in oncology, where Kelly and head of R&D Robert Walker highlighted the role of CD8 T-cell activation in tumor killing. Walker said the company is looking at endpoints including tumor size, tumor shrinkage, infiltrating TIL cells, and surface markers. Longer-term pipeline areas include autoimmune disease, neurological disorders, and Alzheimer's disease.
On the infectious-disease side, a single-season immunogenicity study for a European COVID-flu combination candidate is expected in about a year. A pentavalent C. difficile vaccine candidate could enter the clinic as early as 2027, targeting a multi-billion-dollar market.
Sanofi began shipping NUVAXOVID to U.S. pharmacies over the weekend prior to the summit, with major retailers expected to stock the vaccine by week's end. International launches are underway or prepared in Canada, Germany, and Sweden. IQVIA data on market-share trends will be tracked over the next eight to ten weeks.
Novavax shares have returned 46.6% year to date, though the stock carries a beta of 2.45. The global vaccine market is estimated at roughly $60 billion, with the top five markets accounting for about $30 billion. Standalone COVID and flu vaccines each represent annual markets of approximately $5 billion to $6 billion, and pharmacy channels account for more than 90% of COVID vaccine distribution in the U.S.
